AI in Caribbean Healthcare: A Sector Risk and Safety Briefing

AI is now present in every Caribbean health system that has updated its electronic medical records, signed a contract with a major imaging vendor, deployed a clinical decision support tool, or installed a public-facing patient chatbot. The presence is uneven, often under-documented, and rarely accompanied by the safety scaffolding the same system would demand for a new drug or a new device. This briefing is for the Caribbean ministries of health, regional health authorities, hospital boards, medical councils, and clinical leaders who are now being asked to take responsibility for a category of technology their predecessors did not have to govern.

The aim is concrete: where AI is already operating in Caribbean healthcare, which failure modes deserve immediate attention, what the regulatory expectations are likely to look like, and the safety controls a Caribbean health institution can adopt before its first incident.

Where AI Is Already Showing Up

Six categories of clinical AI use are now visible across the regional health sector.

Radiology and pathology imaging. Several Caribbean tertiary hospitals are using AI-assisted review for chest x-rays, mammography, CT, and pathology slides. The vendor base is largely North American and European. The training data, with rare exceptions, was not Caribbean. The intended use varies from second-reader workflows to triage prioritisation to draft reporting.

Clinical decision support. Sepsis early-warning, ICU deterioration prediction, drug-interaction checking, and antibiotic stewardship modules are embedded in major Caribbean EMR deployments. Most clinicians using them are unaware which decisions are AI-supported and which are rule-based.

Telemedicine triage. Caribbean telemedicine platforms, including those serving the OECS through inter-island arrangements, increasingly use AI to triage symptom reports, route calls, and draft after-visit summaries. The platforms are foreign-built. The patient populations are not.

Patient-facing chatbots. Several Caribbean ministries of health and several regional NGOs operate public-facing chatbots for appointment booking, vaccination information, mental-health signposting, or sexual and reproductive health support. These are commonly built on foreign large language models with light Caribbean configuration.

Health insurance and benefits adjudication. Caribbean health insurers and managed-care providers use AI in claims adjudication, fraud detection, and prior authorisation. Decisions made by these systems determine whether patients receive care promptly.

Public-health surveillance. Caribbean disease surveillance, especially around dengue, COVID-19, and now vector-borne illness, increasingly incorporates AI-supported analytics. The Caribbean Public Health Agency and several national systems use foreign analytics platforms.

Why Caribbean Healthcare AI Carries Distinct Risk

The general failure modes of clinical AI are well-documented in the international literature. Five Caribbean-specific factors compound them.

Population fit. Caribbean patient populations include conditions and presentations under-represented in foreign training data: sickle cell disease, dengue, chikungunya, certain pulmonary tuberculosis presentations, and the cardio-metabolic patterns typical of Afro-Caribbean and Indo-Caribbean populations. An imaging or risk model that performs well on a North American cohort may misbehave on Caribbean patients in ways the vendor did not test for.

Staffing density. Caribbean public hospitals frequently operate with thinner clinical staffing than their North American or European counterparts. A tool that is designed as a "second reader" with the expectation of senior physician review is being adopted, in practice, as a primary reader because the senior physician is not available. The safety assumptions of the vendor do not hold.

Connectivity and data quality. Cloud-dependent clinical AI tools require reliable connectivity and consistent EMR data quality. Several Caribbean health facilities, particularly outside the capital cities, operate with periodic connectivity loss and uneven data standards. The tools degrade in known and unknown ways under those conditions.

Regulatory readiness. Caribbean medical councils, pharmacy boards, and ministry-of-health regulatory units have decades of experience licensing physicians, registering drugs, and inspecting facilities. AI as a regulated clinical tool is a newer category. The capacity to evaluate, approve, and monitor it is still being built across the region.

Litigation and informed consent. Caribbean tort systems generally follow common-law principles on informed consent. The use of AI in a clinical decision is, increasingly, considered material to the consent conversation in comparable jurisdictions. Caribbean institutions that have not updated their consent practices to address AI use are accumulating litigation exposure that will surface in due course.

The Failure Modes That Matter Most

Five failure modes deserve immediate attention from Caribbean health leaders.

Silent population-shift errors. An imaging or risk model performs at the vendor-advertised level on the global average and notably worse on a Caribbean subgroup. The institution sees the overall metric and accepts the deployment. The harm accrues on a subset of patients who would have been better served by a slower, human-led workflow.

Triage de-prioritisation of underrepresented conditions. A general triage AI is unfamiliar with sickle cell crises, with the early presentations of certain tropical infections, or with the symptom combinations common in Caribbean elderly populations. It de-prioritises those presentations. The clinical team, time-pressured, accepts the triage order.

Drift after vendor updates. The model that was validated last quarter has been retrained by the vendor. The performance on the local population has shifted. The institution has not been notified and has no monitoring layer that would detect the shift.

Prompt-injection of patient-facing chatbots. A public-facing health chatbot, designed for appointment booking or symptom triage, is manipulated by adversarial inputs into returning incorrect medical guidance. The patient acts on the guidance. The institution is liable.

Insurance and benefits denial without effective appeal. An AI-driven adjudication denies a Caribbean patient a procedure or medication, often citing pattern-matching against codes that do not reflect the patient's actual indication. The patient and their physician have no clear path to a human re-review on a clinically meaningful timeline.

What Caribbean Hospitals and Clinics Should Be Doing

Six steps move the institution measurably toward safer AI use.

Inventory the AI in your operations. Every Caribbean hospital should be able to produce, on request, a list of every AI-supported clinical or administrative function in its systems, with the vendor, intended use, deployment date, and a named accountable person. Most cannot do this today. The inventory is the foundation of everything else.

Add AI to the clinical-governance committee agenda. Major AI deployments and AI incidents should be tabled at the same committee that reviews medication errors, surgical incidents, and infection rates. AI is a clinical-governance question, not an IT question.

Update informed consent. Where AI is materially involved in a clinical decision, the patient should be told. The consent form does not need to itemise every model. It does need to disclose AI use in plain language.

Require population-fit documentation. No clinical AI vendor should be onboarded without producing evidence that their tool was validated, in part, on a population resembling the Caribbean cohort to which it will be applied. Where that evidence does not exist, the deployment proceeds only with compensating clinical controls.

Build monitoring. Even modest monitoring (weekly distribution of outputs, monthly review of disagreement cases, periodic spot audits by senior clinicians) catches a meaningful share of failure modes early. This work belongs to clinical leadership, not vendor support.

Practice the incident response. Caribbean hospitals are experienced at running drills for code-blue, mass-casualty, and infection outbreaks. An AI safety drill, conducted at least annually, should be added to that programme.

What Caribbean Health Regulators Should Be Doing

Three steps would meaningfully raise the Caribbean regulatory floor.

Publish sector-specific AI use expectations. Caribbean ministries of health, working with medical councils and pharmacy boards, should set out, in writing, what they expect of institutions deploying AI in clinical pathways. The publication does not need to be a rulebook. It needs to make clear that the institutional steps above are expected practice and will, over time, be inspected.

Require AI incident reporting. AI incidents in clinical settings should be added to existing adverse-event reporting frameworks. This creates the data on which proportionate Caribbean clinical AI regulation can eventually be built.

Coordinate regionally. The Caribbean Public Health Agency, CARICOM's health unit, and the regional medical councils have done credible joint work in other domains. AI in healthcare is a clean candidate for the same approach: shared evaluation expectations, shared incident-sharing, and a shared regional voice in the international clinical AI standards work that is happening this year and next.

What Caribbean Health Insurers Should Be Doing

Caribbean health insurers and managed-care providers face a distinct accountability profile. Two priorities matter most.

Define and disclose the role of AI in claims and prior-authorisation decisions. The default in many Caribbean markets is opacity. The trajectory of comparable jurisdictions is toward disclosure, often legislated. Insurers that adopt clear disclosure now will avoid a costly retrofit later.

Build a credible human-review path for AI-driven denials. The credibility test is whether a clinically meaningful review is available on a clinically meaningful timeline, not whether the appeal form exists. Insurers that fail this test will face regulatory and reputational consequences disproportionate to the cost savings the AI tool was supposed to deliver.

Frequently Asked Questions

Is clinical AI safe enough for routine Caribbean deployment?

For well-bounded use cases, with appropriate population-fit documentation, monitoring, and human-in-the-loop design, yes. For unbounded autonomous deployment in high-stakes clinical decisions, no. The judgement is per-tool and per-use, not a blanket sector position.

What about telemedicine in the OECS and across the Eastern Caribbean?

Telemedicine deserves particular attention because the same AI triage tool is used across populations and clinical contexts that vary considerably. The cross-border data flow also raises data-protection questions that need explicit attention.

Should Caribbean medical schools teach AI safety?

Yes, as a sustained component of clinical training, not a one-off module. The University of the West Indies' medical faculties, the University of Guyana, and the regional schools should aim, within the next academic cycle, to include AI safety in the core curriculum.

How should a Caribbean hospital evaluate a vendor's clinical AI claims?

Ask for the validation study, the population characteristics, the sub-group performance, the failure-mode documentation, and the post-deployment monitoring approach. If the vendor cannot produce these, do not deploy. The information asymmetry between vendor marketing and clinical reality is the central safety risk.

What is CAIRMC's role in Caribbean clinical AI?

CAIRMC supports Caribbean health institutions, regulators, and professional bodies on AI risk and governance. We do not certify clinical AI tools. We help the institutions that procure and deploy them build the governance, monitoring, and incident-response practices that produce safer outcomes.

The Caribbean Health Bottom Line

AI in Caribbean healthcare is at the stage where the choices made now will set the standard for the next decade. The Caribbean health systems that adopt AI with the same seriousness they bring to drug registration, device approval, and clinical governance will deliver better patient outcomes and avoid the litigation, regulatory, and trust consequences that follow preventable incidents. The systems that adopt AI as a procurement convenience, without the surrounding governance, will face those consequences in the order in which they arrive. The work in front of us is not unfamiliar. It is the work the Caribbean has done well before in other clinical-safety domains, applied to a new class of tool.